Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: A narrative and systematic review

Journal of Critical Care

Volumn 29, Issue 6, 2014, Pages 1089-1095

  Yusuf, Erlangga ^a   Spapen, Herbert ^a   Piérard, Denis ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Infection; Intensive care; Pharmacodynamic; Pharmacokinetic; Piperacillin tazobactam; Prolonged infusion

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG INTERMITTENT THERAPY; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; AGED; ANALOGS AND DERIVATIVES; BLOOD; CRITICAL ILLNESS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; META ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84908116924     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2014.07.033     Document Type: Article

References (46)

1. Blondiaux N., Wallet F., Favory R., Onimus T., Nseir S., Courcol R.J., et al. Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010, 35(5):500-503. [Epub 2010/03/17].
2. Sorgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993, 31(Suppl A):39-60. [Epub 1993/01/01].
3. Acar J.F., Goldstein F.W., Kitzis M.D. Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993, 31(Suppl A):23-28. [Epub 1993/01/01].
4. Andes D., Anon J., Jacobs M.R., Craig W.A. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004, 24(2):477-502. [Epub 2004/06/05].
5. Barbosa T.M., Levy S.B. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 2000, 3(5):303-311. [Epub 2001/08/11].
6. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44(3):357-363. [Epub 2007/01/06].
7. Lodise T.P., Lomaestro B., Rodvold K.A., Danziger L.H., Drusano G.L. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004, 48(12):4718-4724. [Epub 2004/11/25].
8. Bulitta J.B., Duffull S.B., Kinzig-Schippers M., Holzgrabe U., Stephan U., Drusano G.L., et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007, 51(7):2497-2507. [Epub 2007/05/09].
9. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003, 17(3):479-501. [Epub 2004/01/09].
10. Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37(3):840-851. [quiz 59; Epub 2009/02/25].
11. Langgartner J., Lehn N., Gluck T., Herzig H., Kees F. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007, 53(5):370-377. [Epub 2007/09/06].
12. Patel G.W., Patel N., Lat A., Trombley K., Enbawe S., Manor K., et al. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009, 64(2):236-240. [Epub 2009/06/09].
13. Abdul-Aziz M.H., Dulhunty J.M., Bellomo R., Lipman J., Roberts J.A. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2012, 2(1):37. [Epub 2012/08/18].
14. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66(Suppl 2):ii25-ii31.
15. Falagas M.E., Tansarli G.S., Ikawa K., Vardakas K.Z. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013, 56(2):272-282. [Epub 2012/10/18].
16. Hayashi Y., Roberts J.A., Paterson D.L., Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010, 6(8):1017-1031. [Epub 2010/07/20].
17. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., Falagas M.E. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5(9):581-589. [Epub 2005/08/27].
18. Mah G.T., Mabasa V.H., Chow I., Ensom M.H. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. Ann Pharmacother 2012, 46(2):265-275. [Epub 2012/01/26].
19. Roberts J.A., Lipman J., Blot S., Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Curr Opin Crit Care 2008, 14(4):390-396. [Epub 2008/07/11].
20. Fahimi F., Ghafari S., Jamaati H., Baniasadi S., Tabarsi P., Najafi A., et al. Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia. Indian J Crit Care Med 2012, 16(3):141-147. [Epub 2012/11/29].
21. Goncalves-Pereira J., Oliveira B.S., Janeiro S., Estilita J., Monteiro C., Salgueiro A., et al. Continuous infusion of piperacillin/tazobactam in septic critically ill patients-a multicenter propensity matched analysis. PLoS One 2012, 7(11):e49845.
22. Waxier C., Hu D. Clinical outcomes of prolonged-infusion piperacillin/tazobactam in patients admitted to the intensive care unit. Crit Care Med 2012, 40(12):U101.
23. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101(10):3765-3777. [Epub 2003/01/25].
24. Smith B.S., Yogaratnam D., Levasseur-Franklin K.E., Forni A., Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012, 141(5):1327-1336. [Epub 2012/05/04].
25. Udy A.A., Roberts J.A., Boots R.J., Paterson D.L., Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010, 49(1):1-16. [Epub 2009/12/17].
26. Udy A.A., Putt M.T., Shanmugathasan S., Roberts J.A., Lipman J. Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 2010, 35(6):606-608. [Epub 2010/03/24].
27. Rafati M.R., Rouini M.R., Mojtahedzadeh M., Najafi A., Tavakoli H., Gholami K., et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006, 28(2):122-127. [Epub 2006/07/04].
28. Dulhunty J.M., Roberts J.A., Davis J.S., Webb S.A., Bellomo R., Gomersall C., et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013, 56(2):236-244. [Epub 2012/10/18].
29. Zelenitsky S.A., Ariano R.E., Zhanel G.G. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011, 66(2):343-349. [Epub 2010/10/12].
30. Roberts J.A., Kirkpatrick C.M., Roberts M.S., Dalley A.J., Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35(2):156-163. [Epub 2009/12/19].
31. Angus B.J., Smith M.D., Suputtamongkol Y., Mattie H., Walsh A.L., Wuthiekanun V., et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 50(2):184-191. [Epub 2000/08/10].
32. Tam V.H., McKinnon P.S., Akins R.L., Rybak M.J., Drusano G.L. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002, 50(3):425-428. [Epub 2002/09/03].
33. Mouton J.W., den Hollander J.G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994, 38(5):931-936. [Epub 1994/05/01].
34. Duszynska W., Taccone F.S., Switala M., Hurkacz M., Kowalska-Krochmal B., Kübler A. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs. Int J Antimicrob Agents 2012, 39(2):153-158.
35. Joukhadar C., Frossard M., Mayer B.X., Brunner M., Klein N., Siostrzonek P., et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29(2):385-391. [Epub 2001/03/14].
36. Roberts J.A., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration?. Crit Care Med 2009, 37(3):926-933. [Epub 2009/02/25].
37. Boselli E., Breilh D., Cannesson M., Xuereb F., Rimmele T., Chassard D., et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4g/0.5g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30(5):976-979.
38. Lau W.K., Mercer D., Itani K.M., Nicolau D.P., Kuti J.L., Mansfield D., et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006, 50(11):3556-3561. [Epub 2006/08/31].
39. Lee G.C., Liou H., Yee R., Quan C.F., Neldner K. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 2012, 34(12):2297-2300. [Epub 2012/12/01].
40. Lorente L., Jimenez A., Martin M.M., Iribarren J.L., Jimenez J.J., Mora M.L. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009, 33(5):464-468. [Epub 2009/01/20].
41. Falagas M.E., Lourida P., Poulikakos P., Rafailidis P.I., Tansarli G.S. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014, 58(2):654-663. [Epub 2013/10/02].
42. van Tulder M., Furlan A., Bombardier C., Bouter L. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 2003, 28(12):1290-1299. Editorial Board of the Cochrane Collaboration Back Review G, [Epub 2003/06/18].
43. Dow R.J., Rose W.E., Fox B.C., Thorpe J.M., Fish J.T. Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center. Infect Dis Clin Pract 2011, 19(6):413-417.
44. Yost R.J., Cappelletty D.M. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 2011, 31(8):767-775.
45. Arnold H.M., Hollands J.M., Skrupky L.P., Smith J.R., Juang P.H., Hampton N.B., et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Ann Pharmacother 2013, 47(2):170-180. [Epub 2013/01/24].
46. Dulhunty J.M., Roberts J.A., Davis J.S., Webb S.A., Bellomo R., Gomersall C., et al. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resusc 2013, 15(3):179-185. [Epub 2013/08/16].